Literature DB >> 17620546

Heterogeneity within a large kindred with frontotemporal dementia: a novel progranulin mutation.

A C Bruni1, P Momeni, L Bernardi, C Tomaino, F Frangipane, J Elder, T Kawarai, C Sato, S Pradella, Y Wakutani, M Anfossi, M Gallo, S Geracitano, A Costanzo, N Smirne, S A M Curcio, M Mirabelli, G Puccio, R Colao, R G Maletta, A Kertesz, P St George-Hyslop, J Hardy, E Rogaeva.   

Abstract

BACKGROUND: Frontotemporal dementia (FTD) in several 17q21-linked families was recently explained by truncating mutations in the progranulin gene (GRN).
OBJECTIVE: To determine the frequency of GRN mutations in a cohort of Caucasian patients with FTD without mutations in known FTD genes.
METHODS: GRN was sequenced in a series of 78 independent FTD patients including 23 familial subjects. A different Calabrian dataset (109 normal control subjects and 96 FTD patients) was used to establish the frequency of the GRN mutation.
RESULTS: A novel truncating GRN mutation (c.1145insA) was detected in a proband of an extended consanguineous Calabrian kindred. Segregation analysis of 70 family members revealed 19 heterozygous mutation carriers including 9 patients affected by FTD. The absence of homozygous carriers in a highly consanguineous kindred may indicate that the loss of both GRN alleles might lead to embryonic lethality. An extremely variable age at onset in the mutation carriers (more than five decades apart) is not explained by APOE genotypes or the H1/H2 MAPT haplotypes. Intriguingly, the mutation was excluded in four FTD patients belonging to branches with an autosomal dominant mode of inheritance of FTD, suggesting that another novel FTD gene accounts for the disease in the phenocopies. It is difficult to clinically distinguish phenocopies from GRN mutation carriers, except that language in mutation carriers was more severely compromised.
CONCLUSION: The current results imply further genetic heterogeneity of frontotemporal dementia, as we detected only one GRN-linked family (about 1%). The value of discovering large kindred includes the possibility of a longitudinal study of GRN mutation carriers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17620546     DOI: 10.1212/01.wnl.0000265220.64396.b4

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  24 in total

1.  Frequency of progranulin mutations in a German cohort of 79 frontotemporal dementia patients.

Authors:  Johannes Carolus Magnus Schlachetzki; Klaus Schmidtke; Jan Beckervordersandforth; Wiktor Borozdin; Christian Wilhelm; Michael Hüll; Jürgen Kohlhase
Journal:  J Neurol       Date:  2009-07-19       Impact factor: 4.849

2.  Amyloid in dementia associated with familial FTLD: not an innocent bystander.

Authors:  Georges Naasan; Gil D Rabinovici; Pia Ghosh; Jonathan D Elofson; Bruce L Miller; Giovanni Coppola; Anna Karydas; Jamie Fong; David Perry; Suzee E Lee; Jennifer S Yokoyama; William W Seeley; Joel H Kramer; Michael W Weiner; Norbert Schuff; William J Jagust; Lea T Grinberg; Mochtar Pribadi; Zhongan Yang; Renee Sears; Eric Klein; Kevin Wojta; Howard J Rosen
Journal:  Neurocase       Date:  2015-06-04       Impact factor: 0.881

3.  Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage.

Authors:  Katherine R Smith; John Damiano; Silvana Franceschetti; Stirling Carpenter; Laura Canafoglia; Michela Morbin; Giacomina Rossi; Davide Pareyson; Sara E Mole; John F Staropoli; Katherine B Sims; Jada Lewis; Wen-Lang Lin; Dennis W Dickson; Hans-Henrik Dahl; Melanie Bahlo; Samuel F Berkovic
Journal:  Am J Hum Genet       Date:  2012-05-17       Impact factor: 11.025

4.  Genetic and epigenetic study of an Alzheimer's disease family with monozygotic triplets.

Authors:  Ming Zhang; Allison A Dilliott; Roaa Khallaf; John F Robinson; Robert A Hegele; Michael Comishen; Christine Sato; Giuseppe Tosto; Christiane Reitz; Richard Mayeux; Peter St George-Hyslop; Morris Freedman; Ekaterina Rogaeva
Journal:  Brain       Date:  2019-11-01       Impact factor: 13.501

5.  The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration.

Authors:  Chang-En Yu; Thomas D Bird; Lynn M Bekris; Thomas J Montine; James B Leverenz; Ellen Steinbart; Nichole M Galloway; Howard Feldman; Randall Woltjer; Carol A Miller; Elisabeth McCarty Wood; Murray Grossman; Leo McCluskey; Christopher M Clark; Manuela Neumann; Adrian Danek; Douglas R Galasko; Steven E Arnold; Alice Chen-Plotkin; Anna Karydas; Bruce L Miller; John Q Trojanowski; Virginia M-Y Lee; Gerard D Schellenberg; Vivianna M Van Deerlin
Journal:  Arch Neurol       Date:  2010-02

6.  Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers.

Authors:  Claudia Jacova; Ging-Yuek R Hsiung; Itthipol Tawankanjanachot; Katie Dinelle; Siobhan McCormick; Marjorie Gonzalez; Hyunsoo Lee; Pheth Sengdy; Phoenix Bouchard-Kerr; Matthew Baker; Rosa Rademakers; Vesna Sossi; A Jon Stoessl; Howard H Feldman; Ian R Mackenzie
Journal:  Neurology       Date:  2013-09-04       Impact factor: 9.910

7.  Circulating progranulin as a biomarker for neurodegenerative diseases.

Authors:  Roberta Ghidoni; Anna Paterlini; Luisa Benussi
Journal:  Am J Neurodegener Dis       Date:  2012-08-02

Review 8.  New approaches to the treatment of frontotemporal lobar degeneration.

Authors:  Keith A Vossel; Bruce L Miller
Journal:  Curr Opin Neurol       Date:  2008-12       Impact factor: 5.710

9.  Novel MAPT Val75Ala mutation and PSEN2 Arg62Hys in two siblings with frontotemporal dementia.

Authors:  Maura Gallo; Carmine Tomaino; Gianfranco Puccio; Francesca Frangipane; Sabrina A M Curcio; Livia Bernardi; Silvana Geracitano; Maria Anfossi; Maria Mirabelli; Rosanna Colao; Franca Vasso; Nicoletta Smirne; Raffaele G Maletta; Amalia Cecilia Bruni
Journal:  Neurol Sci       Date:  2009-09-19       Impact factor: 3.307

Review 10.  Progranulin mutations as risk factors for Alzheimer disease.

Authors:  David C Perry; Manja Lehmann; Jennifer S Yokoyama; Anna Karydas; Jason Jiyong Lee; Giovanni Coppola; Lea T Grinberg; Dan Geschwind; William W Seeley; Bruce L Miller; Howard Rosen; Gil Rabinovici
Journal:  JAMA Neurol       Date:  2013-06       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.